Iovance Biotherapeutics Inc. has released a corporate presentation detailing its achievements and ongoing initiatives in the field of Tumor Infiltrating Lymphocytes $(TIL)$ therapy for cancer treatment. The company has treated over 1,000 commercial and clinical patients with its TIL products and reported more than $210 million in total product revenue. Their portfolio includes two approved products and numerous clinical trials across various cancer types, including advanced melanoma and non-small cell lung cancer. Iovance is actively involved in regulatory filings beyond the U.S. and continues to expand its treatment centers globally. The presentation highlights the company's focus on developing innovative therapies to address unmet medical needs. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。